文献速递血栓与止血

血友病死亡分类框架在Emicizumab全球安全数据库中的应用

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database.
PubMed 文献 · J Thromb Haemost · 2021-01-01

本研究将Roche Emicizumab全球安全数据库中截至2020年5月15日报告的31例先天性血友病A患者死亡事件,按报告者评估的因果关联进行分类。结果显示无血栓相关死亡,最常见为出血(11/31),无独特死亡风险与emicizumab预防治疗相关。

要点

  • 31例死亡中出血最常见(11/31),无血栓相关死亡。
  • 死亡中位年龄58岁,51%有FVIII抑制物。
  • 无独特死亡风险与emicizumab预防治疗相关。

核心结论

  • 在PwcHA中,emicizumab预防治疗未关联独特死亡风险,死亡主要与出血或非血友病A相关状况有关,且报告者未认为与emicizumab治疗相关。

研究设计与样本

  • 应用死亡事件分类算法,对Roche Emicizumab全球安全数据库中所有PwcHA死亡报告(来自临床试验、上市前准入和上市后自发报告)进行分类,不重新评估报告的死因。

主要发现

  • 截至2020年5月15日,共报告31例服用emicizumab的PwcHA死亡,死亡中位年龄58岁,51%有FVIII抑制物。
  • 15例被认为与血友病A相关,其中出血11/31(6例有危及生命出血史,4例有颅内出血史),HIV/HCV 3/31,其他肝脏原因1/31。
  • 无病例被归类为血栓性;10例被认为与血友病A无关,中心血管(非血栓)2例、感染/脓毒症5例、创伤/自杀、肺部和恶性肿瘤各1例;6例未明确。

临床怎么用

  • 临床中emicizumab预防治疗的死亡风险主要与出血或非血友病A相关状况有关,报告者未认为与emicizumab治疗相关。

局限性

  • 报告的死因未重新评估,分类基于报告者评估的因果关联;数据截至2020年5月15日。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As the first non-factor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community. OBJECTIVES: We applied an algorithm for categorization of fatal events contemporaneous to emicizumab using reporter-assessed causality documented in the Roche Emicizumab Global Safety Database. PATIENTS/METHODS: All fatalities in PwcHA reported to the database (from clinical trials, pre-market access, and spontaneous post-marketing reports) were categorized into: associated with hemophilia A-hemorrhagic, thrombotic, human immunodeficiency virus (HIV)/hepatitis C virus (HCV), hepatic (non-HCV); associated with general population-trauma/suicide, non-HA-associated conditions; or, unspecified. Reported cause of death was not reassessed. RESULTS: As of cut-off May 15, 2020, 31 fatalities in PwcHA taking emicizumab were reported. Median age at death was 58 years; 51% had factor VIII inhibitors. Fifteen fatalities were considered associated with HA; overall, the most frequent category was hemorrhage (11/31). Of these, six had a history of life-threatening bleeds, and four had a history of intracranial hemorrhage. The remaining HA-associated fatalities were related to HIV/HCV (3/31) and other hepatic causes (1/31). No cases were categorized as thrombotic. Of 10 cases considered not associated with HA, two were categorized as cardiovascular (non-thrombotic), five as infection/sepsis, and one each of trauma/suicide, pulmonary, and malignancy. Six cases were unspecified. CONCLUSIONS: No unique risk of death was associated with emicizumab prophylaxis in PwcHA. The data reveal that mortality in PwcHA receiving emicizumab was primarily associated with hemorrhage or non-HA-associated conditions, and was not reported by treaters to be related to emicizumab treatment.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Peyvandi F, Mahlangu JN, Pipe SW, et al. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021. PMID: 33331041. doi:10.1111/jth.15187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。